Expertise in
4
conditions

Therese Aurran

Marseille, FR 
Expertise in
4
conditions
Marseille, FR 

Overview

Therese Aurran practices practicing medicine in Marseille, France.

Ms. Aurran is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Waldenstrom Macroglobulinemia, and Leukemia.

She is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Evolution of Body Connection and Identity Post-surgery: The Pancreas Cancer Case
Evolution of Body Connection and Identity Post-surgery: The Pancreas Cancer Case
Enrollment Status: Completed
Publish Date: June 18, 2025
Intervention Type: Behavioral
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Lenalidomide and GA101
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

23 Total Publications

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.
Journal: EClinicalMedicine
Published: July 30, 2025

Frequently Asked Questions about Therese Aurran

Is Therese Aurran a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Therese Aurran is classified as an Distinguished expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Therese Aurran participate in research or clinical trials?

Yes. Therese Aurran has published 23 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Therese Aurran's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Aurran's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile